Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Editorial: It's Not About The Size Of Your Pipeline...

This article was originally published in Scrip

Executive Summary

Scrip affiliate Pharmaprojects has been on its annual field trip into the drug pipeline, and the data crunch shows that GlaxoSmithKline has held onto its position as the company with the most drugs in development for another year, despite a year-on-year drop in the number of drug candidates on its books from 258 to 242.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts